Search results
Showing 346 to 360 of 721 results for must
frailty, people with high levels of multimorbidity or polypharmacy).Such trials must be rigorous, with clear identification and...
Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)
NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
This quality standard covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in adults, young people and children (aged 3 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS39Show all sections
Sections for QS39
- Quality statements
- Quality statement 1: Confirmation of diagnosis
- Quality statement 2: Identification and referral in adults
- Quality statement 3: Continuity of child to adult services
- Quality statement 4: Parent training programmes
- Quality statement 5: Psychological treatments for children and young people
- Quality statement 6: Starting drug treatment
- Quality statement 7: Annual review of drug treatment
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.
View quality statements for QS31Show all sections
Sections for QS31
- Quality statements
- Quality statement 1: Warm, nurturing care
- Quality statement 2: Collaborative working between services and professionals
- Quality statement 3: Stability and quality of placements
- Quality statement 4: Support to explore and make sense of identity and relationships
- Quality statement 5: Support from specialist and dedicated services
- Quality statement 6: Continuity of services for placements outside the local authority or health boundary
- Quality statement 7: Support to fulfil potential
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns
Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)
NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.